In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.

Published Date: 03 Jun 2024

According to experts, the benefit-risk profile may alter the way CML is treated.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.

2.

Reducing social media to an hour a day boosts young people's self-image.

3.

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

4.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

5.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot